Atara Biotherapeutics (0HIY) Share Forecast & Price Target
0HIY Analyst Ratings
Moderate Buy
2Buy0Hold0Sell
Based on 2 analysts giving stock ratings to Atara Biotherapeutics in the past 3 months
0HIY Stock 12 Month Forecast
Average Price Target
$15.50▲(90.89% Upside)Based on 2 Wall Street analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. The average price target is $15.50 with a high forecast of $18.00 and a low forecast of $13.00. The average price target represents a 90.89% change from the last price of $8.12.
Past 12 Months12 Month ForecastDec2025Sep2026
High$18.00
Average$15.50
Low$13.00
Highest Price TargetHighest$18.00Average Price Target$15.50Lowest Price TargetLowest$13.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| John Newman | Canaccord Genuity | $13 | buy | 60.10%Upside | Reiterated | 10/14/26 | ||
| Salim Syed | Mizuho Securities | $18 | buy | 121.67%Upside | Reiterated | 08/31/26 | ||
| Ilya Zubkov | Freedom Capital Markets | $4→$10 | hold | 23.15%Upside | Upgraded | 05/18/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| John Newman | 10/14/26 | $13 | buy | 60.10%Upside | Reiterated | Canaccord Genuity | ||
| Salim Syed | 08/31/26 | $18 | buy | 121.67%Upside | Reiterated | Mizuho Securities | ||
| Ilya Zubkov | 05/18/26 | $4→$10 | hold | 23.15%Upside | Upgraded | Freedom Capital Markets |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Atara Biotherapeutics
3 Months
Success Rate14/42 ratings generated profit
33%
Average Return
-7.77%
Copying Salim Syed's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -7.77% per trade.
1 Year
Success Rate7/42 ratings generated profit
17%
Average Return
-34.96%
Copying Salim Syed's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -34.96% per trade.
2 Years
Success Rate6/42 ratings generated profit
14%
Average Return
-50.16%
Copying Salim Syed's trades and holding each position for 2 Years would result in 14.29% of your transactions generating a profit, with an average return of -50.16% per trade.
0HIY Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 2 | 3 |
| Buy | 1 | 1 | 0 | 0 | 1 |
| Hold | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 4 | 4 | 3 | 2 | 4 |
In the current month, 0HIY has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0HIY average Analyst price target in the past 3 months is 15.50.
0HIY Financial Forecast
Consensus$0.00
0HIY Sales Forecast
Next quarter’s sales forecast for 0HIY is $0 with a range of ― to ―. The previous quarter’s sales results were $630.00K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0HIY Stock Forecast FAQ
What is GB:0HIY’s average 12-month price target, according to analysts?
Based on analyst ratings, Atara Biotherapeutics’s 12-month average price target is $15.50.
What is GB:0HIY’s upside potential, based on the analysts’ average price target?
Atara Biotherapeutics has 90.89% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Atara Biotherapeutics a Buy, Sell or Hold?
Atara Biotherapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Atara Biotherapeutics’s share price target?
The average share price target for Atara Biotherapeutics is $15.50. This is based on 2 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $18.00, and the lowest forecast is $13.00. The average share price target represents a 90.89% increase from the current price of $8.12.
What do analysts say about Atara Biotherapeutics?
Atara Biotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Street analysts.
How can I buy shares of Atara Biotherapeutics?
To buy shares of GB:0HIY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.